Controversies in Brain Metastasis Management: Interactive Case-Based Discussion - 2020 Annual Meeting
This course will present four challenging brain metastases cases and variations thereof that speak to the following themes: multiple brain metastases, brain metastases responsive to systemic therapy agents, complications of radiotherapy including neurocognitive effects, and large radiotherapy targets. Each case will have input from multiple perspectives including a medical oncology perspective, an international perspective, and an advanced radiotherapy perspective. Audience participation will be encouraged through interactive feedback based on multiple-choice questions to the audience about how they would manage cases.
The activity is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, radiation physicists, radiation therapists, radiation dosimetrists, nurses, and radiation oncology residents.
- Assess treatment options for brain metastases including advanced radiotherapy techniques and systemic therapy options.
- Apply their knowledge of radiotherapy and systemic therapy options to provide the personalized care to patients and appropriate referrals.
- Vinai Gondi, MD is employed at Northwestern Medicine Cancer Center Warrenville and Northwestern Medicine Chicago Proton Center and receives compensation from UpToDate and RaySearch.
- Seema Nagpal, MD is employed at Department of Neurology, Stanford Cancer Institute and has investment interest from Biocept, Seattle Genetics, and Novocure. Dr. Nagpal has research grants from Biocept, BergHealth, LLC, Inovio, Pharmabcine, and Agios.
- Hidefumi Aoyama, MD, PhD is employed at Department of Radiation Oncology, Hokkaido University Faculty of Medicine and has no financial relationships with a commercial interest.
- Eric A. Mellon, MD, PhD is employed at Department of Radiation Oncology, University of Miami/Sylvester Comprehensive Cancer Center and has no financial relationships with a commercial interest.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.